

Review Article

Ketogenic Diet in Clinical Populations – A Review

Zemer A¹; Samaei S²; Yoel U³; Biderman A⁴; Pincus Y^{1,2,5*}¹Department of Pharmacology and Clinical Biochemistry, Ben Gurion University of the Negev, Israel²Department of Health and Exercise Science, University of Oklahoma, Oklahoma, USA³Endocrinology Unit, Soroka University Medical Center, Israel⁴Department of Family Medicine, Goldman Medical School, Ben-Gurion University of the Negev and Clalit Health Services, Israel⁵Harold Hamm Diabetes Center, Oklahoma, USA***Corresponding author: Pincus Y**

Department of Health and Exercise Science, University of Oklahoma, 1401 Asp Ave., Norman, OK 73019, USA.

Tel: 1-405-325-5349

Email: ypincus@ou.edu

Received: April 05, 2024**Accepted:** May 06, 2024**Published:** May 13, 2024

Introduction

Ketogenic Diet (KD) is a high-fat, low-Carbohydrate (CHO) diet [1], in which the amount of daily CHO consumption is <50 or even <20 g/day - approximately 5-10% of total daily caloric intake [2-4]. This is equivalent to 1-3 CHO exchange servings (e.g. 1-3 slices of bread) a day. Under fasting conditions or CHO restriction, metabolic products of lipid β -oxidation in the liver form ketone bodies (including acetoacetate and β -hydroxybutyrate (β -OHB)), which are also oxidized to produce energy. The accumulation of ketone bodies in the circulation is termed ketosis (serum β -OHB=0.5-5 mmol/l) and represents a physiological response to low CHO availability. Various forms of KD are being promoted as promising treatments for numerous health conditions from chronic headaches [5] to different forms of cancer [6]. Many individuals utilize a KD for weight-loss, due to its contribution to increased appetite control, and reduced adiposity [7], and KDs are increasingly becoming more popular [8].

However, there is an ongoing debate regarding the safety of KD, and the potential health risks that might be associated with long-term exposure to KD. One of the major concerns is the chronic elevated levels of circulating lipids and lipoproteins - particularly LDL [9], which is a Cardiovascular Disease (CVD) risk factor.

Abstract

Ketogenic Diet (KD) is a high-fat, low-Carbohydrate (CHO) diet, designed to induce a metabolic state of ketosis in which the body metabolizes lipids instead of CHO for energy production. Various forms of KD are being promoted as promising treatments for numerous health conditions from chronic headaches to weight-loss and even different forms of cancer and are becoming increasingly more popular. KD appears to be an efficacious approach for weight-loss, and maintenance, improved glycemia, cognitive function and cancer prognosis. However, there is an ongoing debate regarding the safety of KD, and the potential health risks that might be associated with long-term exposure to KD, and in some cases, there is a gap between the acceptance and utilization of KD in individuals with health conditions and the criticism and negative attitudes towards KD by some clinicians. Many individuals choose to follow KD and are encouraged by the positive results they experience. Even though we cannot yet endorse KD or recommend it as a first line of treatment, we, as clinicians, need to educate ourselves about KD, and offer our support and our medical supervision. This way we can ensure that within the boundaries of KD, our patients will make good and healthy dietary choices, and prevent clinical disengagement in extreme cases. To that end, there is an urgent need for good quality research to address the issues of long-term safety of KD in different clinical population and for standardization of KD both in research and in the clinic.

In this review, we will explore some of the different ways in which KD is being used in the treatment of several medical conditions, while addressing some the potential risks of KD in clinical populations. We focus on pediatric epilepsy, weight-loss, diabetes management, neurodegenerative diseases, and cancer.

Pediatric Epilepsy

Epilepsy is characterized by recurrent seizures - brief episodes of involuntary movements, caused by excessive electrical activation in different neurons of the brain. Current prevalence is estimated to be 760 per 100,000 people worldwide, making it one of the most common neurological diseases globally [10]. Although different dietary interventions were used to treat seizures since 500 BC, KD was introduced in the early 1920's, as a novel way to treat pediatric epilepsy [11]. Some mechanisms were suggested for the beneficial effects on epileptic seizures, from synaptic protection through activation of K^{ATP} channels [12], to anti-inflammatory [13], and antioxidant effects that were associated with ketosis [14,15]. The introduction of modern anti-epileptic drugs in the late 1930's, resulted in near complete abandonment of KD as treatment for epilepsy. Moreover, the difficulty in meeting the strict dietary limitations associated with KD and as a result failing to maintain a proper state of ke-

tosis made this treatment regime not sustainable for many, and also played a role in its neglect [11]. Even though later work demonstrated that less drastic low-CHO diets also presented beneficial seizure-moderating effects [16], anticonvulsant drugs eventually replaced most of the dietary interventions for epilepsy [11].

Nowadays an estimated 20%-30% of epileptic patients experience drug-resistance and do not benefit from the available antiepileptic medications [17,18]. For such patients, KD is still a viable and successful treatment option [19]. The effects of KD on epilepsy appear to be age dependent, as several studies in drug-resistant pediatric epilepsy report higher rates of seizure cessation in infants compared to older kids. Although KD shows great promise, resulting in complete elimination of seizures in approximately one third of infants who were <1.5 years old at initiation of KD, these rates were much lower in children who were >1.5 years old at initiation of KD [20]. Similar results were reported when KD was compared to the less strict Modified Atkins Diet (MAD). KD was more favorable in seizure reduction in infants with refractory epilepsy under 2 years of age, these differences were not replicated in children 2-6 years and 6-18 years old. The proportion of subjects with > 50% reduction in seizure prevalence at 6 months was 59%, 38%, and 22% vs. 45%, 41%, and 19% in KD vs. MAD in infants <2 years, 2-6, and 6-18 years old, respectively [21]. Other studies also report that the rates of seizure reduction in children with epilepsy on KD were not fully replicated in adults, and that the effects of KD intervention in epileptic adults are less conclusive [19].

Although some potential adverse effects might exist in long-term KD in young children, like bone fractures, kidney stones and delayed growth, these were reported in only one study and the research evidence is not strong [2]. KD is still an efficacious treatment option, recommended by physicians in cases of medication-resistant epilepsy [22]. Current (2018) guidelines of the International-Ketogenic-Diet-Study-Group, recommend to strongly consider KD in children who failed 2 antiseizure drugs, and that the specific KD used should be individualized for the child and their family – while being supported and guided by a KD team, including a neurologist and a nutritionist [2]. The KD team should see the children every 3 months in the first year of KD initiation and every 6 months thereafter. In addition, it is recommended that children on a KD will be supplemented with multivitamins and calcium to prevent potential deficiencies. The group also states that discontinuation of KD is recommended after 3 months if not efficacious in reducing seizures, but if seizure control is nearly complete (>90% reduction), and no side effects are apparent, KD can be practiced for several years. In most cases KD is terminated after 2 years of initiation [2]. Notably, very similar recommendations were made more recently (2023) by the Italian-League-Against-Epilepsy-Dietary-Therapy-Study-Group [23].

Weight-Loss

Obesity is a state of excess adipose tissue that adversely affects health. Clinically, obesity is determined as a Body Mass Index (BMI) > 30 kg/m². The prevalence of adult obesity in the USA is 41.9% while 73.6% of Americans are overweight (BMI>25), and rates are at a constant rise also in children [24].

The etiology of obesity is multifactorial, but excessive CHO consumption – particularly highly processed CHO is a major cause for obesity and its comorbidities [25]. CHO comprises approximately 55% of the macronutrients in the Standard Ameri-

can Diet (SAD) [8]. KD is very effective in inducing weight-loss, as early as 2 weeks [26] and even when compared to some weight-loss medications like Orlistat [27]. This is attributed at least in part, to the low-CHO content which increases lipolysis and lipid oxidation and reduces adipose tissue mass [28]. Many individuals living with obesity struggle with weight-loss and the promise of KD makes it very popular for weight-loss – even in individuals who are not clinically categorized as obese [29].

Several measures of adiposity were improved following 10 weeks of KD, compared to SAD in overweight individuals [30]. Similarly, several studies report that 6 months of KD resulted in a significant weight-loss, in a quasi-experimental design [31] as well as in randomized controlled trials, when compared to a low-calorie, low-fat diet [32,33]. Moreover, the weight-loss and improved body composition are also associated with reduced blood glucose and lipids [32]. Additionally, compared to low-fat control diet, KD also resulted in increased resting energy expenditure and thermic effect of feeding following weight-loss, which also makes KD a good strategy for weight maintenance [34].

These findings suggest that KD should be recommended as a potent and safe strategy for weight-loss and improved metabolism in individuals living with obesity. However, it was suggested that these beneficial effects do not last. A meta-analysis of 13 articles analyzing the effect of 12 months of KD in obesity concluded that although KD is a beneficial tool for weight-loss, the rate of weight-loss was lower during the 7-12 months compared to the first 6 months of the diet [9]. Moreover, KD may result in a greater loss of muscle mass compared to low-fat diets [35]. A comprehensive study testing changes in metabolic rate (RMR) and body composition found that 4 weeks of KD resulted in weight-loss and a slight increase in RMR but lean mass declines were greater compared to high-CHO diet [26]. Conversely, 52 weeks of calorie-restricted KD did not impair muscle strength or physical function and had similar changes to body composition compared to isocaloric high-fat diet [36]. The effects of KD on muscle mass are yet to be corroborated, but the proposed mechanisms might be a combination of lower insulin and higher corticosterone in the blood, and decreased secretion of Insulin-like Growth Factor (IGF-1) and inhibition of muscle protein synthesis [35]. Maintaining adequate protein content in the KD might help to preserve muscle mass during weight-loss, but more research is needed to fully appreciate the effects of KD on muscle mass and protein synthetic activity, especially when physical activity is incorporated as a complimentary weight-loss strategy [35].

In summary, KD is a very efficacious approach for weight-loss, and maintenance, with some reported adverse effects, however no strong evidence to determine that these outweigh the potential benefits. Additionally, although long-term use of KD (> 1 year) for weight-loss was successful, it did not result in superior weight-loss rates compared to other dietary approaches.

Diabetes Management

Diabetes affects millions of people worldwide and causes various health complications including heart disease, blindness, renal failure, and peripheral nerve damage. Type 1 diabetes (T1D) is characterized by a complete insulin deficiency and required exogenous insulin administration. Type 2 Diabetes (T2D) is typically characterized by insulin resistance, accompanied by hyperinsulinemia and hyperlipidemia and is highly associated with adiposity. There is no cure for diabetes (T1D or T2D), and

current clinical goals are successful diabetes management using diet, physical activity and medications, aimed at controlling glycemia (HbA1C <7%) [37]. KD seems to be beneficial for controlling blood glucose primarily due to the restricted CHO and reliance on ketones for energy production. KD has also been found to decrease circulating markers of systemic inflammation, which can contribute to the improved glycemia [38]. In fact, CHO restriction as a form of diabetes treatment is not a new concept and was the only available treatment in the pre-insulin era. In his textbook from 1892, William Osler prescribed for diabetic patients a diet with only 3% CHO but high in fat (65%) – very similar to modern day KD [39]. The benefits of KD for individuals with T2D also include increased lipolysis, significant weight-loss and reduction of blood triglycerides, and together with other changes these result in decreased insulin resistance [40]. However, there is a scarcity of evidence as to the long-term efficacy of KD in maintaining improved glycemia in diabetes or whether the potential risks associated with KD might outweigh its potential metabolic benefits [41].

Type 2 Diabetes

Several short-term studies (<24 weeks) in individuals with T2D consistently show significant weight-loss (6-11% decrease), reduced HbA1C (16-17% reduction) and high rates of cessation of diabetes medications (80 -95% of participants) following KD [42,43], even if KD was administered as an online intervention [44]. However, it is not clear if these beneficial outcomes persist in the long-term. A meta-analysis of 36 trials (n=2161) comparing KD to low-fat diet reported that while HbA1C levels decreased more with KD in the short-term (<12 months), by 1 year the mean difference between the diets was reduced by approximately 75% [45]. Although other studies report significant weight-loss and improved glycemic control (decreased HbA1c and cessation of diabetes medications) following 12 months of KD [46], in their meta-analysis van-Zuuren et al., report that difference in these beneficial effects between the diet groups completely disappeared at 2 years [45]. One of the suggested reasons for the diminished effects of KD with time is the difficulty in long-term adherence to KD [45,47], however adherence was not evaluated in this analysis [45].

An interesting alternative to KD, that is based on the metabolic principles of CHO-restriction was suggested by Chang et al. [48], using a very-low-CHO high fat breakfast with moderate CHO consumption during the rest of the day. The authors reported decreases in overall postprandial glycemia, glycemic variability and over-all hunger sensation following this ketogenic-breakfast approach in 23 adults with T2D. This strategy might be sufficient to promote the metabolic benefits of KD in individuals with T2D but without the potential long-term risks of KD – but more research is required before this can be determined.

Type 1 Diabetes

The use of KD in T1D as a complimentary strategy to insulin treatment is gaining popularity since optimal glycemic control (HbA1C <7%) is only achieved by 15.8% of individuals with T1D and that dietary CHO has been identified as a major cause for glycemic excursions [49]. Conversely, an observational study, albeit smaller in scale (n=11 patients with T1D), on self-selected long-term KD (2.6 ± 3.3 years), showed remarkable HbA1c levels (5.3±0.4%) and long duration of euglycemic time (74±20% of the time). Nevertheless, 0.9 daily episodes of hypoglycemia were noted (3.6% of the time with blood glucose <3.0 mmol/l), and dyslipidemia was prominent, as total cholesterol, LDL, and

total-cholesterol/HDL-cholesterol ratio were above the recommended range in over 60% of participants. Notably, HDL levels remained within the recommended range [50]. Similarly, an online survey of over 300 adults and children with T1D who followed KD for approximately 2 years on average, reported a mean HbA1C=5.67±0.66% with negligible number of adverse events [51]. This is astonishing, considering the sample size and that this HbA1C value is similar to that of individuals with no diabetes.

The benefits of restricting CHO in individuals with T1D are apparent in several other studies, showing stable 24-hour glycemia, a blunted postprandial glucose response and lower insulin dosing [52,53]. A study using continuous glucose monitors in individuals with T1D, treated with an insulin pump reported that only one week of KD resulted in increased time in glucose Target Range (TIR) and decreased time below Target Range (TBR) and decreased glucose variability [54]. However, a more moderate limitation of CHO consumption might be enough to achieve beneficial metabolic outcomes in individuals with T1D. Krebs et al. [55], utilized a moderate CHO-restriction strategy, with CHO consumption restricted only to <75 g/day and not to the typical <50 g/day commonly used in KD. This resulted in improved glycemic control and reduced insulin requirements without a significant weight-loss following 12 weeks on that diet. Additionally, no significant changes in blood glucose variability or blood lipid profile were found [55]. The long-term effects of such approach, and how it compares to low-fat diet or KD remains to be examined.

When reviewing current literature, even with the increasing reports of beneficial outcomes of KD in individuals with T1D, there is still a considerable lack of adequate evidence, particularly long-term randomized controlled trials, to support a generalized clinical recommendation to use KD in individuals with T1D. In a recent review by Dr. David Ludwig – a longtime advocate for KD, several very compelling arguments were made in favor of using KD in T1D, primarily addressing the contribution of CHO load to glycemic excursions and the potential for KD to improve glycemia, minimize daily insulin requirements, and reduce glucose variability. Interestingly, the authors also describe some of the issues with current evidence and mention small sample size and selection bias, short term interventions, and flaws in dietary assessment in the studies they analyzed in that review [56]. The metabolic benefits of KD and its efficacy in weight-loss and improving glycemia, particularly as they relate to individuals with diabetes cannot be ignored. Together with the methodological issues that affect the robustness of the current evidence, they highlight the urgent and profound need for well designed, adequately powered, long-term randomized controlled trials to assess its safety, potential risks, and health outcomes when applied as a clinically mandated and clinically supported treatment.

Currently, the popularity of KD in individuals with T1D is increasing, particularly among highly educated individuals, in a middle to upper socioeconomic status. These individuals are highly motivated and involved in their medical care and have a good understanding of diabetes physiology and technology [49]. Current clinical recommendations do not advocate for KD [57] and in the case of children and adolescents with T1D even recommend against it [58]. This can lead to conflicts between the patients and the clinical team, which might be perceived as dismissive and condescending and might lead to miscommunication and even clinical disengagement of the patients [49].

Cancer

Cancer is the second leading cause of death in the United States, responsible for 22% of annual fatalities [59]. Carcinogenesis results from mutations disrupting genes associated with cellular growth processes [60,61], often caused by exposure to environmental mutagens combined with deficiencies in DNA repair mechanisms [62]. Most tumor cells display a shift to aerobic glycolysis as their main energy pathway [63]. Since ketone metabolism inhibits glycolysis, the prime bioenergetic pathway for many tumors [64,65], cancer cells are vulnerable to CHO-restriction approaches such as KD [66].

In recent years, much focus has been directed to recognizing obesity as a major risk factor for many cancer types [67], prompting increased focus on lifestyle approaches. The potent weight-loss effect of KD makes it an attractive approach to reduce cancer risk by decreasing obesity. Consequently, several clinical investigations conclude that appropriate nutrition can significantly improve outcomes as a complementary therapy [68].

One proposed mechanism linking obesity and cancer involves elevated circulating insulin and Insulin-like Growth Factor 1 (IGF-1) levels, which over-activate the IGF system [69]. This may promote tumor proliferation and progression by interfering with mitogenic signaling pathways [6,70-73]. KD reduces blood glucose, and lowers insulin and IGF-1 activity [74] and provides a metabolic strategy to potentially slow cancer cell expansion. KD also attenuate peritumoral inflammation and edema, key factors enabling invasion and metastasis [9]. Hence, KD shows promising translational potential for integrated cancer treatment [75,76].

It appears that KD may have a beneficial impact particularly in tumors of the central nervous system. Evidently, the most substantial evidence for KD suppressing tumor growth and progression comes from studies on glioblastoma [77]. This is achieved by counteracting their metabolism, reducing inflammation, modulating pathological gene transcription, and influencing the tumor microenvironment [78].

Evidently, a recent meta-analysis showed that KD resulted in a significant reduction in tumor weight and volume as well as prolonged survival time in rodents [79]. Similar results were reported in Humans, showing a significant reduction in tumor growth and size [80-82], and improved survival [83].

In the longest study to date, that examined the clinical efficacy of KD in women with advanced breast cancer over 10-year, 12 months of KD resulted in markedly improved outcomes compared to those who did not use KD [76]. However, a study in rats found that long-term KD led to enhanced growth of renal tumors, attributed to increased growth hormone and fluctuations in IGF-1 levels [84]. This highlights the need for further research into the long-term impacts of KD on cancer development and progression across different organ systems.

While KDs show promise as an adjuvant cancer therapy, they may cause adverse effects in some patients. Multiple studies have reported fatigue, muscle cramps, hypotension, constipation, and unintentional weight-loss in patients on KD [5, 78].

Current evidence suggests KD may work best in combination with conventional or targeted treatments, and may have the greatest benefit when initiated early in cancer progression [85]. KD may improve outcomes and quality of life for cancer pa-

tients, but more research is needed to test KD efficacy in treating a wide variety of tumors, evaluate KD risk in cancer patients and define clinical guideline for KD use in cancer treatment for maximum therapeutic gain.

Neurodegenerative Diseases

Neurodegeneration is a common characteristic of numerous debilitating, incurable diseases, and the prevalence of these conditions is increasing rapidly [86]. A broad range of neurodegenerative disorders impacts the Central Nervous System (CNS), disrupting sensory, motor, and cognitive functions such as vision, hearing, movement, speech and language, and memory [87]. Here, we will focus on the two most common neurodegenerative diseases -Dementia and Parkinson's Disease.

Dementia

Dementia is a general term for a decline in cognitive ability, severe enough to interfere with daily function. Alzheimer's Disease (AD) is the most common type of dementia, accounting for at least two-thirds of dementia cases in people 65 and older [88]. Despite extensive efforts towards prevention and remediation, dementia remains an urgent public health issue, affecting over 50 million people worldwide [89]. The pathogenesis of AD involves brain anatomic changes, including impaired neuronal glucose metabolism and accumulations of amyloid- β plaques and neurofibrillary tangles [90]. Impaired glucose metabolism and insulin resistance have been strongly associated with progressive cognitive deficiency, therefore, the beneficial effects of KD on glycemia and insulin resistance might be protective against AD progression [91-93].

Several studies in animal models of AD showed a positive effect of KD on age-related cognitive decline [94-96]. In Humans, a pilot study in older adults at risk for AD showed that a modified Mediterranean-KD was well-tolerated and was associated with improved outcomes of AD compared to the American-Heart-Association diet [97]. Moreover, KD also resulted in improved daily function and quality of life in older adults with AD [98-100].

Parkinson's Disease

Parkinson's Disease (PD) is another prevalent neurodegenerative disorder, characterized by gradual degeneration of dopamine-producing neurons. Over 1% of people over 60 are impacted by PD. The neuronal damage leads to progressive motor dysfunction and cognitive difficulties [101,102]. People with PD have impaired neuronal glucose metabolism so reliance on ketone metabolism during KD may normalize neuronal metabolism and slow the deterioration in dopamine synthesis [101,103]. Evidence that KD significantly improved motor functions in PD exist from both animal models [102] and Humans [103]. Additionally, a significant improvement in Parkinson Anxiety Scale scores was also reported [104]. KD in patients with PD was found to be both feasible and safe, and resulted in notable improvements in both motor symptoms (tremors, rigidity, balance) and non-motor symptoms (sleep, mood, cognition) [102-104]. Taken together, these studies suggest KD may be a practical complementary therapy that can enhance functional abilities and quality of life for those living with PD, possibly by optimizing neuronal energy metabolism or other protective mechanisms.

Potential Risks

KD is not suitable for everyone, and although data regarding long-term complication is limited, some non-life threatening

adverse effects, such as constipation or diarrhea, headaches, halitosis, muscle cramps, general weakness and micronutrients deficiencies were mentioned [105-107]. Several studies reported increased all-cause mortality risk in individuals on a KD diet [108-110], but in the same cohort, mortality risk was comparable in individuals on a high-CHO diet [109]. Interestingly, vegetable-based KD was associated with lower all-cause mortality risk compared to both high-CHO diet and animal-based KD [109,110]. One of the major concerns of KD, attributable to the high animal fat consumption, is its effect on the lipid profile and a possible increase of CVD risk over time. Evidently, Goldberg et al., reported a case series in which 5 patients on KD demonstrated extreme hypercholesterolemia (3 of 5 patients with cholesterol >500mg/dl) [111]. Similarly, another case series reported 3 patients with a marked acute elevation of total and LDL-cholesterol in otherwise healthy patients on KD [112]. Interestingly, cholesterol levels were lowered in all patients who stopped KD [111,112] or remained on KD but initiated lipid-lowering medication treatment [111]. Similar evidence of KD resulting in hyperlipidemia exist from randomized controlled studies [113,114], and meta-analyses [9,115], but other studies demonstrate minimal change in lipids [116] or even improved lipid profiles following KD in overweight and obese individuals [31-33]. A comprehensive study that examined the effects of KD on markers of CVD in individuals with T2D concluded that 2 years of KD has beneficial effects on lipidemia and did not increase CVD risk [117]. The authors found that in addition to attenuation of atherosclerotic progression (measured as central intima-media thickness), there was a decrease in small LDL particles (which are associated with diabetic dyslipidemia and increased CVD risk), and an increase in the less deleterious larger LDL particles (which resulted in the increase in total LDL cholesterol) [117]. Interestingly, meta-analyses summarizing intervention studies ranging from 6 to 24 months, report elevated LDL following KD, but an increase in HDL was also reported in these studies [9,115,118]. Using flow mediated dilation (FMD, a measure of endothelial function) to evaluate CVD risk yielded conflicting results. Compared to high-CHO diet, 8 weeks of KD did not impair FMD and also resulted in improvements in several blood markers of CVD risk [119]. Similarly, while in a 2016 study of 115 patients living with obesity and T2D, after consuming an energy-restricted-high-carbohydrate (53% of energy) or isocaloric KD (14% carbohydrate, <50 g/day) for 52 weeks (approximately 13 months), Wycherley and colleagues found no difference in FMD between diet groups [120]; In an earlier study (2010), they reported that both diets resulted in improvements in pulse wave velocity (a measure of arterial function), and circulating markers of endothelial function but the KD resulted in impaired FMD [121]. Notably, in both studies, the authors reported similar glycemic improvements and weight-loss between the two isocaloric diet groups [120,121]. Interestingly, a similar study using the same design (52 weeks of energy restricted isocaloric diets) reported that although the energy-restricted KD resulted in similar weight-loss and glycemic control as the isocaloric high-carbohydrate diet, it resulted in improved lipid profile [122].

Together, these findings suggest that in most individuals, KD may not be a major CVD risk factor while in others, which we currently cannot predict, KD will result in increased circulating lipids and lipoproteins and might increase the CVD risk. It is important to acknowledge that by virtue of inducing significant weight-loss, KD might in fact reduce CVD risk, since obesity is recognized as a major CVD risk factor [123].

The discrepancy in lipidemic responses and the degree of vascular function in response to KD between these studies might be attributable to issues with study design and study duration, however, important factors related to diet composition and total caloric content play an important role. Those include the total amount of CHO and the degree of ketosis, the source and quality of dietary fats (e.g. bacon vs. olive oil and salmon) and the inclusion of fruit and vegetables. In most studies – these factors are not evaluated or not reported. Additionally, other factors like obesity or dysmetabolism are likely also important to consider. It seems that genetic predisposition for hyperlipidemia might play a lesser role [111], but it is yet to be systematically evaluated in a long-term study. Since its growing popularity and widespread use, particularly for weight-loss, it is imperative to understand the long-term effects of a KD on blood lipids and consequently its effects on CVD risk.

In addition to the CVD risk concern, when considering KD in individuals with T1D, a potential concern is Diabetic Ketoacidosis (DKA), an acute metabolic complication which result in excessive ketone accumulation and acidosis [56,124]. Several case reports of DKA as a result of KD were published [125-127], but no well-designed randomized controlled studies were found to suggest this is a wide spread phenomenon. When measuring circulating β -OHB in a group of individuals with T1D, on a voluntary KD, Ozoran et al., found mean (\pm SD) β -OHB levels considerably lower (1.2 ± 0.14 mmol/l) than the DKA threshold of >5 mmol/l [128]. Notably, several reports describe the increased risk for euglycemic DKA in individuals with diabetes treated with Sodium-Glucose cotransporter-2 (SGLT-2) inhibitors and KD [129, 130]. In fact, SGLT-2 treatment might be a counter-indication for KD. Another concern of KD in individuals with T1D is related to the high intake of protein, which may increase patients' risk for renal dysfunction [131]. However, 12 months of KD did not have any adverse effects on renal function in individuals living with obesity [132] or T2D [133]. KD was also well tolerated and safe, with no change in renal outcomes in a group of individuals living with T2D with mild diabetic kidney disease, albeit the intervention was very short (approximately 4 months) [134].

Based on the current evidence it seems that KD in individuals with T1D might hold some risks that outweigh the potential benefits, but it is important to acknowledge that the benefits of KD as an adjunctive therapy in T1D cannot be overlooked. Moreover, the significant effects of KD on weight-loss and glycemia, and the relative low risk make KD an attractive therapeutic strategy, at least for periods of under 1 year. It is important to consider however, that a more moderate CHO restriction (<75g/day) resulted in improved measures of glycemic control without the potential deleterious changes in lipid profile that are associated with KD [55].

Conclusions

KD seems to hold several benefits that can improve outcome in various clinical populations. It is becoming more and more popular, and in some cases, there is a gap between its acceptance and utilization in individuals with health conditions and the criticism and negative attitudes towards KD by some clinicians. The metabolic benefits of KD, its efficacy in inducing weight-loss and its beneficial effects on some neurodegenerative diseases cannot be overlooked. KD appears to be well tolerated and safe in most cases. However, there is a serious lack of well designed, properly powered randomized controlled trials that explore KD long-term efficacy and safety.

With the exception of intractable pediatric epilepsy, KD is not recommended by the different clinical societies as an acceptable treatment for conditions like obesity, diabetes, cancer, and neurodegenerative diseases. However, many individuals choose to follow KD and are encouraged by the positive results they experience. Even though we cannot yet endorse KD or recommend it as a first line of treatment, we, as clinicians, need to find ways to contain our patients' choices, educate ourselves about KD, and offer our support and our medical supervision. This way we can ensure that within the boundaries of KD, our patients will make good and healthy dietary choices and include vegetables and healthy dietary fats and avoid processed products that are low in CHO and are marketed as "Keto-friendly". This is important both to ensure healthy choices and to prevent clinical disengagement in extreme cases.

There is an urgent need for good quality research to address the issues of long-term safety of KD in different clinical population and for standardization of KD both in research and in clinical applications. Based on such research, recommendations should be made to include or to avoid KD as a therapeutic strategy in different health conditions.

References

- Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. *Eur J Clin Nutr.* 2013; 67: 789-96.
- Kossoff EH, Zupec-Kania BA, Auvin S, Ballaban-Gil KR, Bergqvist AGC, Blackford R, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. *Epilepsia Open.* 2018; 3: 175-192.
- Dashti HM, Al-Zaid NS, Mathew TC, Al-Mousawi M, Talib H, Asfar SK, et al. Long term effects of ketogenic diet in obese subjects with high cholesterol level. *Mol Cell Biochem.* 2006; 286: 1-9.
- Westman EC, Mavropoulos J, Yancy WS, Volek JS. A review of low-carbohydrate ketogenic diets. *Curr Atheroscler Rep.* 2003; 5: 476-83.
- Di Lorenzo C, Ballerini G, Barbanti P, Bernardini A, D'Arrigo G, Egeo G, et al. Applications of Ketogenic Diets in Patients with Headache: Clinical Recommendations. *Nutrients.* 2021; 13: 2307.
- Bezerra LS and Santos-Veloso MAO. Ketogenic diet and metastasis: A critical review of the literature and possible mechanisms. *Clin Nutr ESPEN.* 2023; 57: 207-212.
- Kossoff EH, McGrogan JR. Worldwide use of the ketogenic diet. *Epilepsia.* 2005; 46: 280-9.
- Abbasi J. Interest in the Ketogenic Diet Grows for Weight Loss and Type 2 Diabetes. *Jama.* 2018; 319: 215-217.
- Bueno NB, Melo ISVD, Oliveira SLD, Ataíde TDR. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. *Br J Nutr.* 2013; 110: 1178-87.
- Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon CS, Dykeman J, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. *Neurology.* 2017; 88: 296-303.
- Wheless JW. History of the ketogenic diet. *Epilepsia.* 2008; 49: 3-5.
- Kim DY, Abdelwahab MG, Lee SH, O'Neill D, Thompson RJ, Duff HJ, et al. Ketones prevent oxidative impairment of hippocampal synaptic integrity through KATP channels. *PLoS One.* 2015; 10: e0119316.
- Dupuis N, Curatolo N, Benoist JF, Auvin S. Ketogenic diet exhibits anti-inflammatory properties. *Epilepsia.* 2015; 56: e95-8.
- Milder J, Patel M. Modulation of oxidative stress and mitochondrial function by the ketogenic diet. *Epilepsy Res.* 2012; 100: 295-303.
- Jarrett SG, Milder JB, Liang LP, Patel M. The ketogenic diet increases mitochondrial glutathione levels. *J Neurochem.* 2008; 106: 1044-51.
- Kossoff EH, McGrogan AR, Bluml RM, Pillas DJ, Rubenstein JE, Vining EP. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. *Epilepsia.* 2006; 47: 421-4.
- Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. *BMJ.* 2014; 348: g254.
- Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. *N Engl J Med.* 2011; 365: 919-26.
- Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. *Cochrane Database Syst Rev.* 2020; 6: Cd001903.
- Dressler A, Trimmel-Schwahofer P, Reithofer E, Gröppel G, Mühlebner A, Samuelli S, et al. The ketogenic diet in infants--Advantages of early use. *Epilepsy Res.* 2015; 116: 53-8.
- Kim JA, Yoon JR, Lee EJ, Lee JS, Kim JT, Kim HD, et al. Efficacy of the classic ketogenic and the modified Atkins diets in refractory childhood epilepsy. *Epilepsia.* 2016; 57: 51-8.
- Kossoff EH, Zupec-Kania BA, Amark PE, Ballaban-Gil KR, Bergqvist AGC, Blackford R, et al. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. *Epilepsia.* 2009; 50: 304-17.
- De Giorgis V, Tagliabue A, Bisulli F, Brambilla I, Camerini A, Cusmai R, et al. Ketogenic dietary therapies in epilepsy: recommendations of the Italian League against Epilepsy Dietary Therapy Study Group. *Front Neurol.* 2023; 14: 1215618.
- Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. *NCHS Data Brief.* 2020: 1-8.
- Mann J, McLean R, Skeaff M, Morenga LT. Low carbohydrate diets: going against the grain. *Lancet.* 2014; 384: 1479-80.
- Hall KD, Chen KY, Guo J, Lam YY, Leibel RL, Mayer LE, et al. Energy expenditure and body composition changes after an isocaloric ketogenic diet in overweight and obese men. *Am J Clin Nutr.* 2016; 104: 324-33.
- Yancy WS Jr, Westman EC, McDuffie JR, Grambow SC, Jeffreys AS, Bolton J, et al. A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss. *Arch Intern Med.* 2010; 170: 136-45.
- Zhu H, Bi D, Zhang Y, Kong C, Du J, Wu X, et al. Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations. *Signal Transduction and Targeted Therapy.* 2022; 7: 11.
- Kang J, Ratamess NA, Faigenbaum AD, Bush JA. Ergogenic Properties of Ketogenic Diets in Normal-Weight Individuals: A Systematic Review. *J Am Coll Nutr.* 2020; 39: 665-675.
- Gibas MK, Gibas KJ. Induced and controlled dietary ketosis as a regulator of obesity and metabolic syndrome pathologies. *Diabetes Metab Syndr.* 2017; 11: S385-s390.
- Westman EC, Yancy WS, Edman JS, Tomlin KF, Perkinset CE. Effect of 6-month adherence to a very low carbohydrate diet program. *Am J Med.* 2002; 113: 30-6.

32. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. *N Engl J Med.* 2003; 348: 2074-81.
33. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, et al. A randomized trial of a low-carbohydrate diet for obesity. *N Engl J Med.* 2003; 348: 2082-90.
34. Ebbeling CB, Swain JF, Feldman HA, Wong WW, Hachey DL, Garcia-Lago E, et al. Effects of dietary composition on energy expenditure during weight-loss maintenance. *Jama.* 2012; 307: 2627-34.
35. Ashtary-Larky D, Bagheri R, Bavi H, Baker JS, Moro T, Mancin L, et al. Ketogenic diets, physical activity and body composition: a review. *British Journal of Nutrition.* 2022; 127: 1898-1920.
36. Wycherley TP, Buckley JD, Noakes M, Clifton PM, Brinkworth GD, Long-term effects of a very low-carbohydrate weight loss diet on exercise capacity and tolerance in overweight and obese adults. *J Am Coll Nutr.* 2014. 33(4): p. 267-73.
37. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic Targets: Standards of Care in Diabetes—2023. *Diabetes Care.* 2022; 46: S97-S110.
38. Forsythe CE, Phinney SD, Fernandez ML, Quann EE, Wood RJ, et al. Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. *Lipids.* 2008; 43: 65-77.
39. Zinman B, Skyler JS, Riddle MC, Ferrannini E, Diabetes Research and Care Through the Ages. *Diabetes Care.* 2017; 40: 1302-1313.
40. McKenzie AL, Hallberg SJ, Creighton BC, Volk BM, Link TM, Abner MK, et al. A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes. *JMIR Diabetes.* 2017; 2: e5.
41. Firman CH, Mellor DD, Unwin D, Brown A. Does a Ketogenic Diet Have a Place Within Diabetes Clinical Practice? Review of Current Evidence and Controversies. *Diabetes Ther.* 2024; 15: 77-97.
42. Yancy WS, Foy M, Chalecki AM, Vernon MC, Westman EC. A low-carbohydrate, ketogenic diet to treat type 2 diabetes. *Nutr Metab (Lond).* 2005; 2: 34.
43. Westman EC, Yancy WS, Mavropoulos JC, Marquart M, McDuffie JR. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. *Nutr Metab (Lond).* 2008; 5: 36.
44. Saslow LR, Mason AE, Kim S, Goldman V, Ploutz-Snyder R, Bayandorian H, et al. An Online Intervention Comparing a Very Low-Carbohydrate Ketogenic Diet and Lifestyle Recommendations Versus a Plate Method Diet in Overweight Individuals With Type 2 Diabetes: A Randomized Controlled Trial. *J Med Internet Res.* 2017; 19: e36.
45. van Zuuren EJ, Fedorowicz Z, Kujipers T, Pijl H. Effects of low-carbohydrate- compared with low-fat-diet interventions on metabolic control in people with type 2 diabetes: a systematic review including GRADE assessments. *The American Journal of Clinical Nutrition.* 2018; 108: 300-331.
46. Saslow LR, Daubenmier JJ, Moskowitz JT, Kim S, Murphy EJ, Phinney SD, et al. Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes. *Nutr Diabetes.* 2017; 7: 304.
47. Keogh JB, Luscombe-Marsh ND, Noakes M, Wittert GA, Clifton PM. Long-term weight maintenance and cardiovascular risk factors are not different following weight loss on carbohydrate-restricted diets high in either monounsaturated fat or protein in obese hyperinsulinaemic men and women. *Br J Nutr.* 2007; 97: 405-10.
48. Chang CR, Francois ME, Little JP. Restricting carbohydrates at breakfast is sufficient to reduce 24-hour exposure to postprandial hyperglycemia and improve glycemic variability. *Am J Clin Nutr.* 2019; 109: 1302-1309.
49. Hancock M, Burns K, Gan SK, Chew GT. Low-carbohydrate diets in type 1 diabetes: balancing benefits and risks. *Curr Opin Endocrinol Diabetes Obes.* 2023; 30: 113-122.
50. Leow ZZX, Guelfi KJ, Davis EA, Jones TW, Fournier PA. The glycaemic benefits of a very-low-carbohydrate ketogenic diet in adults with Type 1 diabetes mellitus may be opposed by increased hypoglycaemia risk and dyslipidaemia. *Diabet Med.* 2018.
51. Lennerz BS, Barton A, Bernstein RK, Dikeman RD, Diulus C, Hallberg S, et al. Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet. *Pediatrics.* 2018; 141: e20173349.
52. Bernstein RK. Virtually continuous euglycemia for 5 yr in a labile juvenile-onset diabetic patient under noninvasive closed-loop control. *Diabetes Care.* 1980; 3: 140-3.
53. Turton JL, Brinkworth GD, Parker HM, Lim D, Lee K, Rush A, et al. Effects of a low-carbohydrate diet in adults with type 1 diabetes management: A single arm non-randomised clinical trial. *PLoS One.* 2023; 18: e0288440.
54. Ranjan A, Schmidt S, Damm-Frydenberg C, Holst JJ, Madsbad S, Norgaard K. Short-term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: A randomized open-label crossover trial. *Diabetes Obes Metab.* 2017; 19: 1479-1484.
55. Krebs JD, Strong AP, Cresswell P, Reynolds AN, Hanna A, Haeusler S. A randomised trial of the feasibility of a low carbohydrate diet vs standard carbohydrate counting in adults with type 1 diabetes taking body weight into account. *Asia Pac J Clin Nutr.* 2016; 25: 78-84.
56. Lennerz BS, Koutnik AP, Azova S, Wolfsdorf JI, Ludwig DS. Carbohydrate restriction for diabetes: rediscovering centuries-old wisdom. *J Clin Invest.* 2021; 131: e142246.
57. Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK, MacLeod J, et al. Nutrition Therapy for Adults with Diabetes or Prediabetes: A Consensus Report. *Diabetes Care.* 2019; 42: 731-754.
58. Neyman A, Hannon TS, Committee on Nutrition. Low-Carbohydrate Diets in Children and Adolescents with or at Risk for Diabetes. *Pediatrics.* 2023; 152: e2023063755.
59. Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. *Clin Nutr.* 2017; 36: 1187-1196.
60. Font-Burgada J, Sun B, Karin M. Obesity and Cancer: The Oil that Feeds the Flame. *Cell Metab.* 2016; 23: 48-62.
61. Wu GY, Thompson JR. The effect of ketone bodies on alanine and glutamine metabolism in isolated skeletal muscle from the fasted chick. *Biochem J.* 1988; 255: 139-44.
62. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. *EMBO Rep.* 2014; 15: 1243-53.
63. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? *Trends Biochem Sci.* 2016; 41: 211-218.
64. Magee BA, Potezny N, Rofe AM, Conyers RA. The inhibition of malignant cell growth by ketone bodies. *Aust J Exp Biol Med Sci.* 1979; 57: 529-39.
65. Seyfried TN, Mukherjee P, Iyikesici MS, Slocum A, Kalamian M, Spinosa JP, et al. Consideration of Ketogenic Metabolic Therapy as a Complementary or Alternative Approach for Managing Breast Cancer. *Front Nutr.* 2020; 7: 21.
66. Schugar RC, Crawford PA. Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. *Curr Opin Clin Nutr Metab Care.* 2012; 15: 374-80.

67. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body Fatness and Cancer--Viewpoint of the IARC Working Group. *N Engl J Med*. 2016; 375: 794-8.
68. Golemis EA, Scheet P, Beck TN, Scolnick EM, Hunter DJ, Hawk E, et al. Molecular mechanisms of the preventable causes of cancer in the United States. *Genes Dev*. 2018; 32: 868-902.
69. Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? *Nat Rev Cancer*. 2014; 14: 709-21.
70. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. *Endocr Rev*. 2007; 28: 20-47.
71. Malaguarnera R, Belfiore A. The insulin receptor: a new target for cancer therapy. *Front Endocrinol (Lausanne)*. 2011; 2: 93.
72. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. *Nat Rev Cancer*. 2008; 8: 915-28.
73. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. *J Nutr*. 2001; 131: 3109s-20s.
74. Meckling KA, O'Sullivan C, Saari D. Comparison of a low-fat diet to a low-carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living, overweight men and women. *J Clin Endocrinol Metab*. 2004; 89: 2717-23.
75. Mukherjee P, Augur ZM, Li M, Hill C, Greenwood B, Domin MA, et al. Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma. *Communications Biology*. 2019; 2: 200.
76. Egashira R, Matsunaga M, Miyake A, Hotta S, Nagai N, Yamaguchi C, et al. Long-Term Effects of a Ketogenic Diet for Cancer. *Nutrients*. 2023; 15: 2334.
77. Weber DD, Aminazdeh-Gohari S, Kofler B. Ketogenic diet in cancer therapy. *Aging (Albany NY)*. 2018; 10: 164-165.
78. Dal Bello S, Valdemarin F, Martinuzzi D, Filippi F, Gigli GL, Valente MI. Ketogenic Diet in the Treatment of Gliomas and Glioblastomas. *Nutrients*. 2022; 14: 3851.
79. Li J, Zhang H, Dai Z. Cancer Treatment with the Ketogenic Diet: A Systematic Review and Meta-analysis of Animal Studies. *Front Nutr*. 2021; 8: 594408.
80. Khodabakhshi A, Akbari ME, Mirzaei HR, Seyfried TN, Kalamian M, Davoodi SH. Effects of Ketogenic metabolic therapy on patients with breast cancer: A randomized controlled clinical trial. *Clin Nutr*. 2021; 40: 751-758.
81. Allen BG, Bhatia SK, Buatti JM, Brandt KE, Lindholm KE, Button AM, et al. Ketogenic diets enhance oxidative stress and radiochemo-therapy responses in lung cancer xenografts. *Clin Cancer Res*. 2013; 19: 3905-13.
82. Weber DD, Aminzadeh-Gohari S, Thapa M, Redtenbacher AS, Catalano L, Capeloa T, et al. Ketogenic diets slow melanoma growth in vivo regardless of tumor genetics and metabolic plasticity. *Cancer Metab*. 2022; 10: 12.
83. Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. *PLoS One*. 2012; 7: e36197.
84. Liśkiewicz AD, Kasprowska D, Wojakowska A, Polanski K, Lewin-Kowalik J, Kotulska K, et al. Long-term High Fat Ketogenic Diet Promotes Renal Tumor Growth in a Rat Model of Tuberous Sclerosis. *Sci Rep*. 2016; 6: 21807.
85. Klement RJ. The emerging role of ketogenic diets in cancer treatment. *Curr Opin Clin Nutr Metab Care*. 2019; 22: 129-134.
86. Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and a new hope. *Dis Model Mech*. 2017; 10: 499-502.
87. Wareham LK, Liddelow SA, Temple S, Benowitz LI, Di Polo A, Wellington C, et al. Solving neurodegeneration: common mechanisms and strategies for new treatments. *Mol Neurodegener*. 2022; 17: 23.
88. Kumar A, Sidhu J, Goyal A, Tsao JW. Alzheimer Disease. In *StatPearls*. Treasure Island (FL): StatPearls Publishing Copyright. 2022.
89. Disease AS. World Alzheimer Report 2019. 2019.
90. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. *Int J Nanomedicine*. 2019; 14: 5541-5554.
91. Rusek M, Pluta R, Ulamek-Kozioł M, Czuczwar SJ. Ketogenic Diet in Alzheimer's Disease. *Int J Mol Sci*. 2019; 20: 3892.
92. Castellano CA, Nugent S, Paquet N, Tremblay S, Bocti C, Lacombe G, et al. Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia. *J Alzheimers Dis*. 2015; 43: 1343-53.
93. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*. 2019; 18: 88-106.
94. Hernandez AR, Hernandez CM, Campos KT, Truckenbrod LM, Sankarya Y, McQuail JA, et al. The Antiepileptic Ketogenic Diet Alters Hippocampal Transporter Levels and Reduces Adiposity in Aged Rats. *J Gerontol A Biol Sci Med Sci*. 2018; 73: 450-458.
95. Newman JC, Covarrubias AJ, Zhao M, Yu X, Gut P, Ng CP, et al. Ketogenic Diet Reduces Midlife Mortality and Improves Memory in Aging Mice. *Cell Metab*. 2017; 26: 547-557.e8.
96. Wang D, Mitchell ES. Cognition and Synaptic-Plasticity Related Changes in Aged Rats Supplemented with 8- and 10-Carbon Medium Chain Triglycerides. *PLoS One*. 2016; 11: e0160159.
97. Neth BJ, Mintz A, Whitlow C, Jung Y, Sai KS, Register TC, et al. Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study. *Neurobiol Aging*. 2020; 86: 54-63.
98. Phillips MCL, Deprez LM, Mortimer GMN, Murtagh DKJ, McCoy S, Mlychreest R, et al. Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease. *Alzheimers Res Ther*. 2021; 13: 51.
99. Newport MT, VanItallie TB, Kashiwaya Y, Todd King M, Veech RL. A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease. *Alzheimers Dement*. 2015; 11: 99-103.
100. Lilamand M, Mouton-Liger F, Di Valentin E, Ortiz MS, Paquet C. Efficacy and Safety of Ketone Supplementation or Ketogenic Diets for Alzheimer's Disease: A Mini Review. *Front Nutr*. 2021; 8: 807970.
101. Grochowska K and Przeliorz A, The Effect of the Ketogenic Diet on the Therapy of Neurodegenerative Diseases and Its Impact on Improving Cognitive Functions. *Dement Geriatr Cogn Dis Extra*. 2022; 12: 100-106.
102. Shaafi S, Najmi S, Aliasgharpour H, Mahmoudi J, Sadigh-Etemad S, Farhoudi M, et al. The efficacy of the ketogenic diet on motor functions in Parkinson's disease: A rat model. *Iran J Neurol*. 2016; 15: 63-9.

103. Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely JFS, Lynch CDP. Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial. *Mov Disord*. 2018; 33: 1306-1314.
104. Tidman MM, White D, and White T, Effects of an low carbohydrate/healthy fat/ketogenic diet on biomarkers of health and symptoms, anxiety and depression in Parkinson's disease: a pilot study. *Neurodegener Dis Manag*. 2022; 12: 57-66.
105. O'Neill B, Raggi P. The ketogenic diet: Pros and cons. *Atherosclerosis*. 2020; 292: 119-126.
106. Yancy WS Jr, Olsen MK, Guyton JR, Bakst RP, Westman EC, A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. *Ann Intern Med*. 2004; 140: 769-77.
107. Churuangasuk C, Griffiths D, Lean MEJ, Combet E, Impacts of carbohydrate-restricted diets on micronutrient intakes and status: A systematic review. *Obes Rev*. 2019; 20: 1132-1147.
108. Mazidi M, Katsiki N, Mikhailidis DP, Sattar N, Banach M. Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies. *Eur Heart J*. 2019; 40: 2870-2879.
109. Akter S, Mizoue T, Nanri A, Goto A, Noda M, Sawada N, et al. Low carbohydrate diet and all cause and cause-specific mortality. *Clin Nutr*. 2021; 40: 2016-2024.
110. Sun C, Zhang WS, Jiang CQ, Jin YL, Deng XQ, Woo J, et al. Low-Carbohydrate Diets and Mortality in Older Asian People: A 15-Year Follow-Up from a Prospective Cohort Study. *Nutrients*. 2022; 14: 1406.
111. Goldberg IJ, Ira J IJ, Ibrahim N, Bredefeld C, Foo S, Lim V, Gutman D, et al. Ketogenic diets, not for everyone. *J Clin Lipidol*. 2021; 15: 61-67.
112. Crosier R, McPherson R. Profound Elevation in LDL Cholesterol Level Following a Ketogenic Diet: A Case Series. *CJC Open*. 2022; 4: 732-734.
113. Retterstøl K, Svendsen M, Narverud I, Holven KB. Effect of low carbohydrate high fat diet on LDL cholesterol and gene expression in normal-weight, young adults: A randomized controlled study. *Atherosclerosis*. 2018; 279: 52-61.
114. Burén J, Ericsson M, Damasceno NRT, Sjödin A. A Ketogenic Low-Carbohydrate High-Fat Diet Increases LDL Cholesterol in Healthy, Young, Normal-Weight Women: A Randomized Controlled Feeding Trial. *Nutrients*. 2021; 13.
115. Mansoor N, Vinknes KJ, Veierød MB, Retterstøl K. Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. *Br J Nutr*. 2016; 115: 466-79.
116. Tay J, Brinkworth GD, Noakes M, Keogh J, Clifton PM, Metabolic effects of weight loss on a very-low-carbohydrate diet compared with an isocaloric high-carbohydrate diet in abdominally obese subjects. *J Am Coll Cardiol*. 2008; 51: 59-67.
117. Athinarayanan SJ, Hallberg SJ, McKenzie AL, Lechner K, King S, McCarter JP, et al. Impact of a 2-year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes. *Cardiovasc Diabetol*. 2020; 19: 208.
118. Luo W, Zhang J, Xu D, Zhou Y, Qu Z, Yang Q, et al. Low carbohydrate ketogenic diets reduce cardiovascular risk factor levels in obese or overweight patients with T2DM: A meta-analysis of randomized controlled trials. *Frontiers in Nutrition*. 2022; 9.
119. Keogh JB, Brinkworth GD, Noakes M, Belobrajdic DP, Buckley JD, Clifton PM, et al. Effects of weight loss from a very-low-carbohydrate diet on endothelial function and markers of cardiovascular disease risk in subjects with abdominal obesity. *Am J Clin Nutr*. 2008; 87: 567-76.
120. Wycherley TP, Thompson CH, Buckley JD, Luscombe-Marsh ND, Noakes M, Wittert GA, et al. Long-term effects of weight loss with a very-low carbohydrate, low saturated fat diet on flow mediated dilatation in patients with type 2 diabetes: A randomised controlled trial. *Atherosclerosis*. 2016; 252: 28-31.
121. Wycherley TP, Brinkworth GD, Keogh JB, Noakes M, Buckley JD, Clifton PM, et al. Long-term effects of weight loss with a very low carbohydrate and low-fat diet on vascular function in overweight and obese patients. *J Intern Med*. 2010; 267: 452-61.
122. Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, et al. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. *Am J Clin Nutr*. 2015; 102: 780-90.
123. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association. *Circulation*. 2021; 143: e984-e1010.
124. Chiasson JL, Jilwan NA, Bélanger R, Bertrand S, Beauregard H, Ekoé JM, et al. Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. *Cmaj*. 2003; 168: 859-66.
125. Blanco JC, Khatiri A, Kifayat A, Cho R, Aronow WS. Starvation Ketoacidosis due to the Ketogenic Diet and Prolonged Fasting - A Possibly Dangerous Diet Trend. *Am J Case Rep*. 2019; 20: 1728-1731.
126. Charoensri S, Sothornwit J, Trirattanapikul A, Pongchaiyakul C. Ketogenic Diet-Induced Diabetic Ketoacidosis in a Young Adult with Unrecognized Type 1 Diabetes. *Case Rep Endocrinol*. 2021; 2021: 6620832.
127. White-Cotsmire AJ, AM Healy. Ketogenic Diet as a Trigger for Diabetic Ketoacidosis in a Misdiagnosis of Diabetes: A Case Report. *Clin Diabetes*. 2020; 38: 318-321.
128. Ozoran H, Matheou M, Dyson P, Karpe F, Tan GD. Type 1 diabetes and low carbohydrate diets-Defining the degree of nutritional ketosis. *Diabet Med*. 2023; 40: e15178.
129. Mistry S, DC Eschler. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature. *AACE Clin Case Rep*. 2021; 7: 17-19.
130. Dorcelly B, Nitis J, Schwartzbard A, Newman JD, Goldberg IJ, Sum M. A Case Report: Euglycemic Diabetic Ketoacidosis Presenting as Chest Pain in a Patient on a Low Carbohydrate Diet. *Curr Diabetes Rev*. 2021; 17: 243-246.
131. Ko GJ, Rhee CM, Kalantar-Zadeh K, Joshi S. The Effects of High-Protein Diets on Kidney Health and Longevity. *J Am Soc Nephrol*. 2020; 31: 1667-1679.
132. Brinkworth GD, Buckley JD, Noakes M, Clifton PM. Renal function following long-term weight loss in individuals with abdominal obesity on a very-low-carbohydrate diet vs high-carbohydrate diet. *J Am Diet Assoc*. 2010; 110: 633-8.
133. Tay J, Thompson CH, Luscombe-Marsh ND, Noakes M, Buckley JD, Wittert GA, et al. Long-Term Effects of a Very Low Carbohydrate Compared with a High Carbohydrate Diet on Renal Function in Individuals With Type 2 Diabetes: A Randomized Trial. *Medicine (Baltimore)*. 2015; 94: e2181.
134. Zainordin NA, Warman NAE, Mohamad AF, Yazid FAA, Ismail NH, Chen XW, et al. Safety and efficacy of very low carbohydrate diet in patients with diabetic kidney disease-A randomized controlled trial. *PLoS One*. 2021; 16: e0258507.